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Synaptic processes and immune-related pathways
implicated in Tourette syndrome
Abstract
Tourette syndrome (TS) is a neuropsychiatric disorder of complex genetic architecture involving multiple interacting
genes. Here, we sought to elucidate the pathways that underlie the neurobiology of the disorder through genome-
wide analysis. We analyzed genome-wide genotypic data of 3581 individuals with TS and 7682 ancestry-matched
controls and investigated associations of TS with sets of genes that are expressed in particular cell types and operate in
specific neuronal and glial functions. We employed a self-contained, set-based association method (SBA) as well as a
competitive gene set method (MAGMA) using individual-level genotype data to perform a comprehensive
investigation of the biological background of TS. Our SBA analysis identified three significant gene sets after Bonferroni
correction, implicating ligand-gated ion channel signaling, lymphocytic, and cell adhesion and transsynaptic signaling
processes. MAGMA analysis further supported the involvement of the cell adhesion and trans-synaptic signaling gene
set. The lymphocytic gene set was driven by variants in FLT3, raising an intriguing hypothesis for the involvement of a
neuroinflammatory element in TS pathogenesis. The indications of involvement of ligand-gated ion channel signaling
reinforce the role of GABA in TS, while the association of cell adhesion and trans-synaptic signaling gene set provides
additional support for the role of adhesion molecules in neuropsychiatric disorders. This study reinforces previous
findings but also provides new insights into the neurobiology of TS.
Introduction
Tourette syndrome (TS) is a chronic neurodevelop-
mental disorder characterized by several motor tics and
at least one vocal tic that persist more than a year1. Its
prevalence is between 0.6 and 1% in school-aged chil-
dren2,3. Although TS is highly polygenic in nature, it is
also highly heritable4. The population-based heritability
is estimated at 0.75,6, with SNP-based heritability ranging
from 21 to 58%4 of the total. The genetic risk for TS that
is derived from common variants is spread throughout
the genome4. The two genome-wide association studies
(GWAS) conducted to date7,8 suggest that TS genetic
variants may be associated, in aggregate, with tissues
within the cortico-striatal and cortico-cerebellar circuits,
and in particular, the dorsolateral prefrontal cortex. The
GWAS results also demonstrated significant ability to
predict tic severity using TS polygenic risk scores7,9. A
genome-wide CNV study identified rare structural var-
iation contributing to TS on the NRXN1 and CNTN6
genes10. De novo mutation analysis studies in trios have
highlighted two high confidence genes, CELSR and
WWC1, and four probable genes, OPA1, NIPBL, FN1,
and FBN2 to be associated with TS11,12.
Investigating clusters of genes, rather than relying on
single-marker tests is an approach that can significantly
boost power in a genome-wide setting13. Common
variant studies can account for a substantial proportion
of additive genetic variance14 and have indeed produced
a wealth of variants associated with neuropsychiatric
disorders, which, however, lack strong predictive qua-
lities, an issue commonly referred to as “missing herit-
ability”15. Theoretical, as well as empirical, observations
have long hinted toward the involvement of non-
additive genetic variance into the heritability of com-
mon phenotypes. As such, pathway analyses could pave
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the way toward the elucidation of missing heritability in
complex disease.
This approach has already proven useful in early
genome-wide studies of TS. The first published TS
GWAS, which included 1285 cases and 4964 ancestry-
matched controls did not identify any genome-wide sig-
nificant loci. However, by partitioning functional- and
cell-type-specific genes into gene sets, an involvement of
genes implicated in astrocyte carbohydrate metabolism
was observed, with a particular enrichment in astrocyte-
neuron metabolic coupling16. Here, we investigated fur-
ther the pathways that underlie the neurobiology of TS,
performing gene set analysis on a much larger sample of
cases with TS and controls from the second wave TS
GWAS. We employed both a competitive gene set ana-
lysis as implemented through MAGMA, as well as a self-
contained analysis through a set-based association
method (SBA). Besides highlighting a potential role for
neuroimmunity, our work also provides further support
for previously implicated pathways including signaling
cascades and cell adhesion molecules.
Materials and methods
Samples and quality control
The sample collection and single variant analyses for the
data we analyzed have been extensively described pre-
viously7,8. IRB approvals and consent forms were in place
for all data collected and analyzed as part of this project.
For the purposes of our analysis, we combined 1285 cases
with TS and 4964 ancestry-matched controls from the
first wave TS GWAS, with 2918 TS cases and 3856
ancestry-matched controls from the second wave TS
GWAS. Standard GWAS quality control procedures were
employed17,18. The data were partitioned first by geno-
typing platform and then by ancestry. The sample call rate
threshold was set to 0.98, and the inbreeding coefficient
threshold to 0.2. A marker call rate threshold was defined
at 0.98, case-control differential missingness threshold at
0.02, and Hardy–Weinberg equilibrium (HWE) threshold
to 10−6 for controls and 10−10 for cases. Before merging
the partitioned datasets, we performed pairwise tests of
association and missingness between the case-only and
control-only subgroups to address potential batch effect
issues. All SNPs with p-values ≤10−06 in any of these
pairwise quality control analyses were removed. After
merging all datasets, principal component analysis was
utilized to remove samples that deviated more than
6 standard deviations and to ensure the homogeneity of
our samples in the ancestry space of the first 10 principal
components, through the use of the EIGENSOFT suite19.
Identity-by-descent analysis with a threshold of 0.1875
was used to remove related samples, and thus to avoid
confounding by cryptic relatedness. After quality control,
the final merged dataset consisted of 3581 cases with TS
and 7682 ancestry-matched controls on a total of 236,248
SNPs, annotated using dbSNP version 137 and the hg19
genomic coordinates.
We assessed the genomic variation in our data through
PCA analysis to identify potential population structure
(Supplementary Fig. 1 and Supplementary Table 1). The
variation in our data was reduced to a triangular shape in
the two-dimensional space of the first two principal
components. One tip was occupied by Ashkenazi Jewish
samples, the second by the Southern European samples,
and the other by the North Europeans. Depicting geo-
graphy, the Southern to Nothern axis was populated by
European-ancestry samples. The first five principal com-
ponents were deemed statistically significant (Tracy
Widom test as implemented by EIGENSOFT, Supple-
mentary Table 1) and were added to the association
model as covariates, in order to avoid population struc-
ture influencing our results.
Gene sets
We collected neural-related gene sets from multiple
studies on pathway analyses in neuropsychiatric dis-
orders16,20–24. These studies relied on an evolving list of
functionally-partitioned gene sets, focusing mainly on
neural gene sets, including synaptic, glial sets, and neural
cell-associated processes. We added a lymphocytic gene
set also described in these studies23, in order to also
investigate potential neuroimmune interactions.
In total, we obtained 51 gene sets, which we transcribed
into NCBI Entrez IDs and subsequently filtered by
removing gene sets that contained fewer than 10 genes.
Forty-five gene sets fit our criteria and were used to
conduct the analyses.
We examined two primary categories of pathway ana-
lysis methods, the competitive 25 and the self-contained
test16,25. The competitive test compares the association
signal yielded by the tested gene set to the association
signals that do not reside in it26,27. In this type of test, the
null hypothesis is that the tested gene set attains the same
level of association with disease as equivalent random
gene sets. In contrast, the self-contained test investigates
associations of each tested gene set with the trait, and not
with other gene sets, meaning that the null hypothesis in
this case is that the genes in the gene set are not asso-
ciated with the trait25,27. Therefore, for a competitive test,
there should be data for the whole breadth of the genome,
but this test cannot provide information regarding how
strongly the gene set is associated with the trait28. We
employ both methods for a comprehensive investigation
into the neurobiological background of TS.
MAGMA on raw genotypes
We ran MAGMA26 on the individual-level genotype
data using the aforementioned filtered gene set lists.
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MAGMA performs a three-step analytic process. First, it
annotates the SNPs by assigning them to genes, based on
their chromosomal location. Then it performs a gene
prioritization step, which is used to perform the final gene
set analysis step. We used a genomic window size of
±10 kb and the top 5 principal components as covariates
to capture population structure. SNP-to-gene assign-
ments were based on the NCBI 37.3 human gene refer-
ence build. The number of permutations required for the
analysis was determined by MAGMA, using an adaptive
permutation procedure leading to 11,263 permutations.
MAGMA employs a family-wise error correction calcu-
lating a significance threshold of 0.00100496.
Set-based association (SBA) test
We conducted SBA tests on the raw individual genotype
data, as described in PLINK25,29 and adapted in a later
publication30. This test relies on the assignment of indi-
vidual SNPs to a gene, based on their position, and thus to
a pathway, according to the NCBI 37.3 human gene
reference build. After single-marker association analysis,
the top LD-independent SNPs from each set are retained
and selected in order of decreasing statistical significance,
and the mean of their association p-values is calculated.
We permuted the case/control status, repeating the pre-
vious association and calculation steps described above,
leading to the empirical p-value for each set. The absolute
minimum number of permutations required for crossing
the significance level is dictated by the number of gene
sets tested. Testing for 45 gene sets requires at least 1000
permutations to produce significant findings. PLINK’s
max(t) test recommends at least 64,000 permutations. We
opted to increase the number of permutations to one
million, the maximum that was computationally feasible,
to maximize our confidence in the outcomes, given our
large sample size.
We used logistic regression as the association model on
the genotypes and the first five principal components as
Fig. 1 Results of gene set analysis as implemented by MAGMA. The gene set that crossed the significance threshold is depicted in red.
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covariates on the genotype data to conduct the SBA test
with the collected neural gene sets. Another repetition of
this step was performed with a simple association test, to
test for this method’s robustness to population structure.
We proceeded to run the analysis on all samples, using all
gene sets at a 10 kb genomic window size, the first five
principal components as covariates, and one million
permutations. Since the permutations were performed on
the phenotypic status of the samples, and only served as a
method of association of the trait with the gene sets, we
also corrected the results by defining the significance
threshold through Bonferroni correction at 1.1 × 10−3
(0.05/45).
Results
For the gene set association analysis, we ran PLINK’s
self-contained set-based association method and MAG-
MA’s competitive association method, using the same 45
gene sets on the processed genotyped data of 3581 cases
and 7682 ancestry-matched controls on a total of 236,248
SNPs. By performing both methods of analysis we aimed
to obtain a global assessment of the gene sets’ relationship
with TS.
MAGMA analysis identified one significant gene set
(Fig. 1), cell adhesion and trans-synaptic signaling
(CATS), which achieved a nominal p-value of 6.2 × 10−5
(permuted p-value of 0.0032). While the CATS gene set is
comprised of 83 genes, MAGMA’s annotation step
prioritized 72 of its genes for the gene set analysis. It
involves 3290 variants that were reduced to 1627 inde-
pendent variants in our data. Results were mainly driven
by associations in the CDH26, CADM2, and OPCML
genes as indicated by MAGMA gene-based analysis
(Table 1). In the gene-based tests, CDH26 attained a
p-value of 8.9526 × 10−6, CADM2 a p-value of 4.6253 ×
10−4, and OPCML a p-value of 7.9851 × 10−4, neither
crossing the genome-wide significance threshold for gene
tests (2.574 × 10−6 calculated on 19,427 genes contained
in the NCBI 37.3 version of RefGene).
We next run SBA, which conducts an initial single-
marker association step before performing permutations
to calculate empirical p-values for the gene sets. This
association step is performed on the total number of
variants that are associated with the genes involved in the
gene sets, leading to a subset of 25,630 variants in our
data, which are then filtered based on their LD. Analysis
identified three gene sets as significant (Table 2), the
ligand-gated ion channel signaling (LICS) (P: 2.67 × 10−4),
the lymphocytic (P: 3.5 × 10−4), and the cell adhesion and
trans-synaptic signaling (CATS) (P: 1.07 × 10−3). Detailed
results for all the tested gene sets are shown in Fig. 2.
The LICS gene set was the top-scoring gene set,
including 38 genes and involving 683 variants, 66 of which
were associated with TS. The gene set’s signal was
primarily driven by variants residing in the genes of the
γ-aminobutyric acid receptors GABRG1 and GABBR2,
the HCN1 channel gene and the glutamate receptor gene
GRIK4. This signal was driven primarily by an association
with SNP rs9790873, which is an eQTL for HCN1 in tibial
nerve, according to GTEx31. GABBR2 is represented by
two top SNPs, that are LD-independent, and removing
either of those SNPs from the gene set did not cause the
gene set to drop under the significance threshold.
The lymphocytic gene set was the next top-scoring gene
set, including 143 genes that translated to 799 variants in
our data, with 50 of these variants associated with TS. Its
signal was driven by a missense variant inside the FLT3
gene and an intergenic variant between NCR1 and NLRP7,
followed by IL12A, HDAC9, CD180. The rs1933437 SNP
is the top variant for FLT3, and is a possibly damaging
missense variant32, located in the sixth exon of the FLT3
gene leading to a p.Thr227Met mutation. It is a very
common variant and the sixth exon appears to be less
expressed than downstream exons. Given the tissues in
which this eQTL affects FLT3’s expression, we tested the
lymphocytic gene set by removing FLT3 from it, to
identify whether the lymphocytic gene set association was
biased by the presence of FLT3. After removing FLT3, the
lymphocytic gene set association statistic decreased
slightly (P: 0.00012), driven mainly by NCR1/NRLP7.
The third significant gene set, CATS, consisted of 83
genes, including multiple large genes. CATS was identi-
fied by both SBA and MAGMA in our analyses, and both
gene set approaches identified CDH26 as the gene with
the lowest p-value. Both SBA and MAGMA also identified
NCAM2, NTM, and ROBO2 as strongly associated with
TS, with NTM represented by two LD-independent SNPs.
CATS’s top SNP, rs1002762, resides in the CDH26 gene
on chromosome 20, and is the top associated SNP in our
data (P: 2.031 × 10−6) with an odds ratio of 1.178.
Notable results from the SBA also include the Astrocyte
small GTPase mediated signaling (ASGMS) and the
Astrocyte-neuron metabolic coupling (ANMC) gene sets,
with a p-values slightly under the significance thresholds.
These gene sets attained a p-value of 0.00137 and
0.001504, respectively.
Discussion
Seeking to elucidate the neurobiology of TS, we present
here the largest study to date aiming to interrogate the
involvement of sets of genes that are related to neuronal
and glial function in TS. We analyzed data from our
recently performed TS GWAS and conducted two distinct
types of testing, a competitive, regression-based test
(MAGMA) and a self-contained, p-value combining test
(SBA). Self-contained tests investigate for associations
with a phenotype, while competitive tests compare a
specific gene set against randomly generated gene sets.
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We employed both methods to perform a comprehensive
investigation of the biological background of TS.
A potential problem in pathway analysis is false SNP
assignment to genes, which in turn may increase false
results. In order to address this issue, most studies in the
literature use short window sizes (10–20 kb) when
assigning SNPs to genes. Here, we used a 10 kb window,
paired with excessive permutations to avoid false assign-
ments, that would introduce false positive results. There is
evidence that long-range SNP effects could play a role,
mostly associated with large insertion/deletion events that
are not in the scope of this study and would likely hamper
the analysis33.
MAGMA’s regression-based algorithm has been
reported to account for gene size biases, as can be also
discerned by the variable sizes of the top genes. MAG-
MA’s top prioritized gene, CDH26, is represented by 4
SNPs in our data, CADM2 by 42, while OPCML is
represented by 210 SNPs, as it covers an extensive
genomic region. We addressed such issues in SBA by
setting a low r2 threshold and conditioning on any LD-
independent SNPs that resided on the same gene.
The gene sets used in our study come from a line of
function-based analyses, aiming to investigate neurobio-
logical mechanisms in neuropsychiatric disorders. A
previous pathway analysis using individual-level genotype
data of the first wave TS GWAS identified genes involved
in astrocytic-neuron metabolic coupling, implicating
astrocytes in TS pathogenesis16. In this study, we took
advantage of the increased sample size of the second wave
TS GWAS and the mechanics of the two distinct methods
to identify gene sets associated with TS that provide a
novel insight into the pathogenesis of TS, and substantiate
the role of neural processes in this neuropsychiatric
disorder.
The ANMC gene set that contains genes involved in
carbohydrate metabolism in astrocytes was the single
identified gene set in the previous pathway analysis study
on TS16, raising a hypothesis on a potential mechanism
that involves altered metabolism of glycogen and gluta-
mate/γ-aminobutyric acid in the astrocytes. In our study,
the ANMC gene set scored slightly under the significance
threshold.
Here, analyzing a much larger sample size we identified
three sets of genes as significantly associated to the TS
phenotype. Among them the LICS gene set, which
involves genes implicated in ion channel signaling
through γ-aminobutyric acid and glutamate. Several genes
in the LICS gene set have been previously implicated in
neuropsychiatric phenotypes. HCN1, a hyperpolarization-
activated cation channel involved in native pacemaker
currents in neurons and the heart, has been significantly
Table 1 Statistically significant result of MAGMA gene set analysis.
Gene set Genes P-value Pcorr
Cell adhesion and transsynaptic signaling 72 6.1736e−05 0.00318
Gene ID Chr Start End SNPs Param N Z-stat P-value Gene name
60437 20 58528471 58593772 4 3 11263 4.2895 8.95e−06 Cadherin 26 (CDH26)
253559 3 85003133 86128579 42 18 11263 3.3124 0.00046 Cell Adhesion molecule 2 (CADM2)
4978 11 132279875 133407403 210 106 11263 3.1564 0.00079 Opioid binding protein/cell adhesion molecule like (OPCML)
1007 5 26875709 27043689 14 7 11263 2.9627 0.0015 Cadherin 9 (CDH9)
4685 21 22365633 22918892 61 29 11263 2.7975 0.0025 Neural Cell adhesion molecule 2 (NCAM2)
961 3 107756941 107814935 6 4 11263 2.6465 0.0040 CD47 molecule (CD47)
1003 16 66395525 66443689 11 6 11263 2.0242 0.021 Cadherin 5 (CDH5)
199731 19 44121519 44148991 4 3 11263 1.984 0.023 CADM4 (cell adhesion molecule 4)
708 17 5331099 5347471 1 1 11263 1.9269 0.026 C1QBP (complement C1q binding protein)
2017 11 70239612 70287690 2 2 11263 1.8709 0.030 CTTN (cortactin)
4045 3 115516210 116169385 56 29 11263 1.8095 0.035 Limbic system-associated membrane protein (LSAMP)
8502 2 159308476 159542941 19 9 11263 1.7503 0.040 Plakophilin 4 (PKP4)
5097 5 141227655 141263361 3 3 11263 1.6903 0.045 PCDH1 (protocadherin 1)
26047 7 145808453 148123090 237 110 11263 1.6621 0.048 Contactin associated protein-like 2 (CNTNAP2)
4155 18 74685789 74849774 49 30 11263 1.6502 0.049 MBP (maltose-binding protein)
The cell adhesion and transsynaptic signaling gene set achieved statistical significance. Genes within this set that achieved nominal significance with gene-based test
implemented by MAGMA are also listed here. Gene ID refers to Entrez ID, Param to the number of SNPs used for the SNP-wise analysis.
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associated with schizophrenia and autism34–36. GABRG1,
an integral membrane protein that inhibits neuro-
transmission by binding to the benzodiazepine receptor,
has yielded mild associations with general cognitive abil-
ity37 and epilepsy38, while GABBR2, a g-protein-coupled
receptor that regulates neurotransmitter release, with
schizophrenia39 and post-traumatic stress disorder40 in
multiple studies. The GABA-ergic pathway has been
previously implicated in TS, and recent advances show-
cased the possibility that a GABA-ergic transmission
deficit can contribute toward TS symptoms41. GRIK4,
encoding a glutamate-gated ionic channel, has shown
associations with mathematical ability and educational
attainment42 and weaker associations with attention-
deficit hyperactivity disorder43. The γ-aminobutyric acid
receptors and the HCN channel, are features of inhibitory
interneurons44 and also identified in the brain tran-
scriptome of individuals with TS45, adding to the evidence
that the phenotype of TS could be influenced by an
inhibitory circuit dysfunction, as has previously been
proposed46.
Individuals with TS are reported to present elevated
markers of immune activation45,47. In addition, a number
of studies have implicated neuroimmune responses with
the pathogenesis of TS48–50. We investigated neu-
roimmune interactions by interrogating association to a
gene set designed by Goudriaan et al.23 to study enrich-
ment in lymphocytic genes. Indeed, our analysis yielded a
statistically significant signal. The FLT3 association
coincides with the results of the second wave TS GWAS,
in which FLT3 was the only genome-wide significant hit7.
FLT3 and its ligand, FLT3LG, have a known role in cel-
lular proliferation in leukemia, and have been found to be
expressed in astrocytic tumors51. The rs1933437 variant
in FLT3 is an eQTL in the brain cortex and the cere-
bellum31, and has also been implicated in the age at the
onset of menarche52. Variants in FLT3 have attained
genome-wide significance in a series of studies focusing
on blood attributes in populations of varying ancestry, and
our current insights into its role are mostly based on these
associations with blood cell counts, serum protein levels,
hypothyroidism, and autoimmune disorders52–55.
FLT3 could play a role in neuroinflammation as sup-
ported by its intriguing association with peripheral neu-
ropathic pain. The inhibition of FLT3 is reported to
alleviate peripheral neuropathic pain (PNP)56, a chronic
Table 2 Statistically significant results of the SBA analysis.
Gene set SNPs NSIG ISIG EMP1
Chr SNP BP A1 F_A F_U A2 P OR Genes implicated
Ligand-gated ion channel signaling 683 66 5 0.000267
4 rs1391174 46072596 T 0.4892 0.4586 C 1.764e−05 1.131 GABRG1(0)
5 rs9790873 45291514 C 0.1535 0.1335 T 5.621e−05 1.177 HCN1(0)
9 rs2259639 101317401 T 0.2751 0.2982 C 0.0003612 0.8928 GABBR2(0)
9 rs1930415 101238974 T 0.2218 0.2424 C 0.0007006 0.8908 GABBR2(0)
11 rs949054 120795888 C 0.2241 0.2053 T 0.001281 1.118 GRIK4(0)
Lymphocytes 799 50 5 0.00035
19 rs16986092 55433696 T 0.1158 0.09473 C 1.093e−06 1.251 NCR1(+9.257 kb)|NLRP7(−1.18 kb)
13 rs1933437 28624294 G 0.4183 0.3871 A 8.482e−06 1.138 FLT3(0)
3 rs2243123 159709651 C 0.2515 0.2759 T 0.0001167 0.8817 IL12A(0)|IL12A-AS1(0)
7 rs3801983 18683672 C 0.1928 0.2133 T 0.0003981 0.8808 HDAC9(0)
5 rs2230525 66478626 C 0.08431 0.07127 T 0.0005641 1.2 CD180(0)
Cell adhesion and transsynaptic signaling 3290 292 5 0.00107
20 rs1002762 58580885 G 0.2305 0.2028 A 2.031e−06 1.178 CDH26(0)
21 rs2826825 22762779 G 0.376 0.3487 A 6.698e−05 1.126 NCAM2(0)
11 rs7925725 131449365 C 0.3709 0.3979 A 0.0001099 0.8921 NTM(0)
11 rs12224080 131816849 G 0.09841 0.08353 A 0.0002519 1.198 NTM(0)
3 rs6773575 77060574 C 0.0964 0.1126 A 0.000256 0.8407 ROBO2(0)
Three pathways achieved significance. Association statistics for the top five SNPs driving the signal in each set are also shown. NSIG is the number of SNPs crossing
the nominal significance threshold. EMP1 is the empirical p-value attained by the tested gene set. P is the p-value of the original single-marker association, OR is the
respective odds ratio. A1 is the minor allele and A2 the major allele. F_A and F_U are the frequencies of the minor allele in case and control samples, respectively.
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neuroimmune condition that arises from aberrations in
the dorsal root ganglia. Cytokines and their receptors have
been at the epicenter of the neuroimmune interactions,
with microglia contributing significantly to chronic phe-
notypes of such states57. FLT3 is a critical component for
neuroimmune interactions, especially in the case of the
development and sustenance of the PNP phenotype.
Interestingly, pain follows sex-specific routes, with glia
having a prominent role for pain propagation in males,
while females involve adaptive immune cells instead58.
These, paired with previous evidence of glial involvement
in TS16, raise an interesting hypothesis for TS symptom
sustenance, since FLT3 has been shown to be critical for
the chronicity of neuronal dysregulations56.
Notably, FLT3 has a prominent role in the hematologic
malignancies, with one-third of adult acute myeloid leu-
kemia (AML) patients presenting with activating muta-
tions in FLT3, and wild-type FLT3 being found
overexpressed in hematologic malignancies. FLT3 is
implicated in apoptotic mechanisms, with its mutations
being associated with59 Warburg effect promotion, inhi-
bition of ceramide-dependent mitophagy60, and induction
of pro-survival signals, through downstream signaling
cascades, including PI3K-Akt-mTOR, Ras/MAPK, and
JAK-STAT. This mitochondrial role of FLT3 has been
further reinforced by findings that associate it with
increased post-transcriptional methylation of mitochon-
drial tRNAs in cancer61. As such, FLT3 is regarded a
molecular target for therapeutic intervention62.
FLT3 is expressed in the cerebellum and whole blood,
while FLT3’s top variant, rs1933437, is an eQTL for FLT3
on GTEx31 in various brain tissues, such as the cortex, the
cerebellum, the hypothalamus, the frontal cortex (BA9),
and non-brain tissues, such as the skin, the pancreas, and
adipose tissues. In order to test the robustness of the
lymphocytic association in our findings, we repeated
the analysis after removing FLT3 from the lymphocytic
gene set. The p-value of the gene set decreased, but still
Fig. 2 Results of gene set analysis as implemented by SBA. The gene sets that crossed the significance threshold are depicted in red.
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remained significant, due to the association in the NCR1/
NLRP7 locus. Besides FLT3, the other genes included in
this gene set are also quite intriguing to consider as
potential candidates that could underlie the pathophy-
siology of TS. In the same vein with FLT3, common
variants in NCR1 have also been significantly associated
with blood protein levels63. HDAC9 has been significantly
associated with androgenetic alopecia52,64, hair color52,
and ischemic stroke65. These seem to follow previous
knowledge, given that genes involved in ischemic stroke
have been identified as a common component between
TS and ADHD66, and that TS, similar to other neu-
ropsychiatric disorders, demonstrates a distinct pre-
ference for males. CD180 has shown associations with
general cognitive ability37.
The CATS gene set involves many cell adhesion mole-
cules, with the top signals found in CDH26. CDH26 is a
cadherin that regulates leukocyte migration, adhesion,
and activation, especially in the case of allergic inflam-
mation67. Cell adhesion molecules have been consistently
implicated in phenotypes related to brain function, with
the latest addition of the high confidence TS gene
CELSR3, a flamingo cadherin, that was identified in a large
scale de novo variant study for TS12. Their relation to TS
has been well documented, with the notable examples of
neurexins, contactins, neuroligins, and their associated
proteins10,68–70. These genes were present in the CATS
gene set but did not reach a level of significance in our
analysis. This hints toward their possible involvement in
TS mostly through rare variants10,68,69, a notion rein-
forced by findings in other neuropsychiatric disorders71,72.
Most of the genes contained in the identified gene sets
in this study are involved in cognitive performance,
mathematical ability, and educational attainment42.
OPCML, CADM2, and ROBO2 have been implicated in
neuromuscular and activity phenotypes, such as grip
strength73, physical activity74, and body mass index52.
ROBO2 has been associated with depression75, expressive
vocabulary in infancy76, while CADM2 is associated to a
multitude of phenotypes, including anxiety75, risk-taking
behavior, and smoking77. NTM displays similar patterns
of pleiotropy, associated with smoking52, myopia64, hair
color78, anxiety75, asperger’s syndrome79, bipolar disorder
with schizophrenia80, and eating disorders81. NCAM2 and
NTM, similarly to the lymphocytic genes, have been sig-
nificantly associated with blood protein levels82 and leu-
kocyte count52, respectively. Many of these phenotypes
are known TS comorbidities, presenting themselves
commonly or less commonly in TS cases, and others
are related to functions that get impaired in TS
symptomatology.
The CATS gene set was identified in both methods
indicating the involvement of cell adhesion molecules in
transsynaptic signaling. Using genotypes with both
methods as a means of identifying pathways instead of
summary statistics, gave our study the edge of sample-
specific linkage disequilibrium rather than relying on an
abstract linkage disequilibrium pattern reference. Our
current understanding for regional structures of the
genome and the cis-effects of genomic organization will
aid the refinement of these associations as well as help
shape our understanding of the pleiotropic mechanisms in
the identified loci potentially responsible for disease
pathogenesis.
In conclusion, our analysis reinforces previous findings
related to TS neurobiology while also providing novel
insights: We provide further support for the role of FLT3
in TS, as well as the possibility for the involvement of the
GABA-ergic biological pathway in TS pathogenesis. At
the same time, our study highlights the potential role of
glial-derived neuroimmunity in the neurobiology of TS
opening up intriguing hypotheses regarding the potential
for gene-environment interactions that may underlie this
complex phenotype.
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